Cover Image
Market Research Report

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 484632
Published Content info 91 Pages
Delivery time: 1-2 business days
Price
Back to Top
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2019
Published: November 25, 2019 Content info: 91 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2019, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Marburg hemorrhagic fever is a rare, acute infectious which affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain and weight loss.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 17, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 2 and 2 molecules, respectively.

Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11551IDB

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Overview
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Companies Involved in Therapeutics Development
    • ANP Technologies Inc
    • BioCryst Pharmaceuticals Inc
    • Collaborations Pharmaceuticals Inc
    • Eisai Co Ltd
    • Emergent BioSolutions Inc
    • Emergex Vaccines Ltd
    • Fab'entech SA
    • Fox Chase Chemical Diversity Center Inc
    • GeoVax Labs Inc
    • Greffex Inc
    • IDBiologics Inc
    • Immunomodulation Inc
    • Integrated BioTherapeutics Inc
    • Intervir Therapeutics
    • Johnson & Johnson
    • Mapp Biopharmaceutical Inc
    • NanoViricides Inc
    • Phoenix Biotechnology Inc
    • Profectus BioSciences Inc
    • Rodos BioTarget GmbH
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drug Profiles
    • (Ebola + Marburg) (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Ebola + Marburg) (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANP-803 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies for Ebola and Marburg Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-5 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eritoran tetrasodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • galidesivir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GEOEM-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GreEMTri - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hemorrhagic fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMM-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • infectious disease vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • marburg vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MBP-091 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MR-78 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-026 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBI-05204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBT-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 1 for Marburgvirus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 2 for Marburgvirus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Ebola and Marburg Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit VP40 for Ebola and Marburg Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SW-456 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tilorone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAC-69120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 12, 2019: IAVI announces award from U.S. Department of Defense to advance Marburg Virus Vaccine candidate development
      • Jul 29, 2019: GeoVax announces 100% protection data from Marburg Virus Vaccine Study
      • Jun 11, 2019: MappBio announces contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure
      • May 09, 2019: BioCryst completes Phase 1 clinical trial of galidesivir
      • Mar 05, 2019: HHS' BARDA funds its first Marburg virus vaccine development
      • Jan 02, 2019: BioCryst initiates phase 1 clinical trial of Galidesivir
      • Jan 10, 2018: TSRI scientists discover workings of first promising Marburg virus treatment
      • Sep 28, 2017: New Research Indicates Expanded Potential Uses For Phoenix Biotech Drug PBI-05204: Inhibits Ebola and Marburg Viruses and Offers Novel Treatment Approaches For Alzheimer's and Parkinson's Diseases
      • Apr 05, 2017: Emergex Multivalent Filovirus vaccine Awarded SBRI Contract by Innovate UK
      • Jan 19, 2016: Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial
      • Nov 17, 2015: Profectus Presents Preclinical Data Demonstrating that a Single Dose of Multi-Component Vaccine Provides Complete Protection Against Zaire and Sudan Species of Ebola Virus and Marburg Virus
      • Apr 08, 2015: Profectus BioSciences Ebola Vaccine Shown Effective and Safe in Providing Rapid, Single-Dose Protection Against Current "Makona" Ebola Outbreak Strain in Non-Human Primates
      • Mar 31, 2015: BioCryst Awarded BCX4430 Advanced Development Contract
      • Mar 25, 2015: IBT Presents Pan-Ebola and Pan-Filovirus Monoclonal Antibodies
      • Jan 22, 2015: NanoViricides Reports That It Has Shipped anti-Ebola Drug Candidates For Testing to a BSL-4 Hi-Security Biocontainment Laboratory
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 4: Products under Development by Companies, H2 2019
  • Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 6: Products under Development by Universities/Institutes, H2 2019
  • Table 7: Number of Products by Stage and Target, H2 2019
  • Table 8: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 9: Number of Products by Stage and Route of Administration, H2 2019
  • Table 10: Number of Products by Stage and Molecule Type, H2 2019
  • Table 11: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by ANP Technologies Inc, H2 2019
  • Table 12: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2019
  • Table 13: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Collaborations Pharmaceuticals Inc, H2 2019
  • Table 14: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Eisai Co Ltd, H2 2019
  • Table 15: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, H2 2019
  • Table 16: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Emergex Vaccines Ltd, H2 2019
  • Table 17: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Fab'entech SA, H2 2019
  • Table 18: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Fox Chase Chemical Diversity Center Inc, H2 2019
  • Table 19: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, H2 2019
  • Table 20: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Greffex Inc, H2 2019
  • Table 21: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by IDBiologics Inc, H2 2019
  • Table 22: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Immunomodulation Inc, H2 2019
  • Table 23: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Integrated BioTherapeutics Inc, H2 2019
  • Table 24: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Intervir Therapeutics, H2 2019
  • Table 25: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Johnson & Johnson, H2 2019
  • Table 26: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Mapp Biopharmaceutical Inc, H2 2019
  • Table 27: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by NanoViricides Inc, H2 2019
  • Table 28: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Phoenix Biotechnology Inc, H2 2019
  • Table 29: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Profectus BioSciences Inc, H2 2019
  • Table 30: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Rodos BioTarget GmbH, H2 2019
  • Table 31: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects, H2 2019
  • Table 32: Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top